Komori
KYORIN Pharmaceutical (4569) · InitiativeFirst stated

Discontinuation of KRP-209 Development

First written in FY2018-Q2. . Latest entry: FY2018-Q2.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Discontinuation of KRP-209 DevelopmentA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2018-Q2First statedAnnual report

    「For KRP-209, a tinnitus treatment, we had conducted a Phase II clinical trial. After completing the trial and evaluating the results, we decided to discontinue development because the expected efficacy of the product was not clearly demonstrated.」

    Development of KRP-209 was discontinued after the Phase II trial failed to clearly demonstrate the expected efficacy.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.